Evaluate Vantage Homepage
The failure of the phase 2 Moonsong outpatient trial prompts a phase 3 rethink and a one-year delay.
With telaglenastat facing a risky trial readout Calithera picks up two bargain-basement oncology projects to pivot to.
The young biotech is well placed to deliver its first pivotal win, but investor focus might lie elsewhere.
Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.
Data are due in the fourth quarter for Aldeyra, Aeglea and Radius, among other small developers.
Deals this week with a UK consortium and Oxford Biomedica see the group bet on lentiviral vectors.
The group’s ambitions are startling, but it will need cash and collaborators to realise them.
The group hopes phase 2 data will back approval for its amyotrophic lateral sclerosis project AMX0035 after all.